Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis
Treatment with tofacitinib was associated with a significant increase in sclerostin serum levels and a parallel decrease in markers of bone formation. However, no significant bone loss was observed.
Authors
- Anna Fratucello
- Giovanni Orsolini (ORCID: https://orcid.org/0000-0003-4119-3016)
- Ombretta Viapiana (ORCID: https://orcid.org/0000-0003-1917-5655)
- Maurizio Rossini (ORCID: https://orcid.org/0000-0001-9692-2293)
- Davide Gatti (ORCID: https://orcid.org/0000-0002-7471-3076)
- Angelo Fassio (ORCID: https://orcid.org/0000-0001-9187-232X)
- Giovanni Adami (ORCID: https://orcid.org/0000-0002-8915-0755)
- Riccardo Bixio (ORCID: https://orcid.org/0000-0001-9335-3371)
- Elena Fracassi (ORCID: https://orcid.org/0000-0003-1354-8115)
Institutions
- University of Verona (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
Publication Details
- Journal
- BMC Rheumatology
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1186/s41927-024-00414-6
- Citations
- 3
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Pfizer